Glioblastoma progression on or after first-line Stupp regimen: MRI evidence of true progr...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-GBM-TRANSFORMATION-PROGRESSION |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-GBM |
| Sources | SRC-EANO-GBM-2024 SRC-NCCN-CNS-2025 |
Red Flag Origin
| Definition | Glioblastoma progression on or after first-line Stupp regimen: MRI evidence of true progression (RANO criteria — distinguished from pseudoprogression by serial imaging / advanced techniques), early recurrence <6 months post-RT (often pseudoprogression — repeat MRI at 4-8 weeks before re-treatment decision), or distant new lesion. Routes from upfront Stupp to recurrent-GBM algorithm (re-resection + bevacizumab / TTF / regorafenib / lomustine / re-irradiation). |
|---|---|
| Clinical direction | intensify |
| Category | transformation-progression |
Trigger Logic
{
"any_of": [
{
"finding": "gbm_rano_progression",
"value": true
},
{
"finding": "gbm_distant_new_lesion",
"value": true
},
{
"finding": "gbm_early_recurrence_lt_6mo_post_rt",
"value": true
}
],
"type": "composite_clinical"
}
Notes
Pseudoprogression occurs in ~30% post-Stupp at 3 mo MRI — does not represent true tumor growth (treatment-related inflammation / radiation effect); RANO criteria require either second confirmatory MRI or outside-RT-field new disease before declaring progression. Confirmed recurrence: re-resection if accessible (gross-total benefit per retrospective series); systemic options include bevacizumab (BELOB, AVAglio — improves PFS, no OS benefit; useful for steroid-sparing edema control), regorafenib (REGOMA), lomustine, TMZ rechallenge if MGMT-methylated and >12 mo PFS to first TMZ. Tumor-treating fields approved for recurrence per EF-11. shifts_algorithm empty pending ALGO-GBM-RECURRENT-2L authoring.
Used By
Indications
IND-GBM-NEWLY-DIAGNOSED-ELDERLY-HYPORT- IND-GBM-NEWLY-DIAGNOSED-ELDERLY-HYPORTIND-GBM-NEWLY-DIAGNOSED-ELDERLY-TMZ- IND-GBM-NEWLY-DIAGNOSED-ELDERLY-TMZIND-GBM-NEWLY-DIAGNOSED-STUPP- IND-GBM-NEWLY-DIAGNOSED-STUPPIND-GBM-RECURRENT-BEVACIZUMAB- IND-GBM-RECURRENT-BEVACIZUMAB